Danshensu for Myocardial Ischemic Injury: Preclinical Evidence and Novel Methodology of Quality Assessment Tool

Abstract

Background: Danshensu (DSS) possesses unique bioactivity on the cardiovascular system. However, there is a lack of systematical summary of DSS for acute myocardial ischemia injury and no quality assessment tool for the systematical review of cell experiments. Here, we aimed to assess the preclinical evidences and possible mechanisms of DSS for myocardial ischemia injury, and to develop a quality assessment tool for the systematical review of cell experiments.Methods: Thirty-two studies with 473 animals and 134 cells were identified by searching seven databases. All data analysis was performed using RevMan 5.3. CAMARADES 10-item checklist was used to assess the methodological quality of animal experiments. A new 10-item checklist was first developed to assess the methodological quality of cell studies.Results: The score of study quality ranged from 3 to 7 points in animal studies, while the cell studies scored 3–6 points. Meta-analysis showed that DSS had significant effects on reducing myocardial infarct (MI) size in vivo, and increasing cell viability and reducing apoptosis rate in vitro compared with controls (P < 0.01). The possible mechanisms of DSS for MI are improving circulation, antioxidant, anti-apoptosis, anti-inflammatory, promoting angiogenesis, anti-excessive autophagy, anti-calcium overload, and improving energy metabolism.Conclusions: DSS could exert cardioprotective effect on myocardial ischemia injury, and thus is a probable candidate for further clinical trials andtreatment of AMI. In addition, the newly devloped 10-item checklist for assessing methodological quality of cell study that recommened to use the sysmatic review of cell studies.

Notoginsenoside R1 for Organs Ischemia/Reperfusion Injury: A Preclinical Systematic Review

“…According to CAMARADES 10-item checklist, the score of the included studies was medium. They are similar to other animal studies, and the main limitations were that no study reported sample size calculation, allocation concealment, and blinding of outcome assessment (Bao et al, 2018). Inadequate sample size could not reach the approximately threshold with sufficient power and efficacy (Bacchetti 2010).…”

“…The modified item is the use of anesthetic with no intrinsic organ-protective activity. Our newly developed scale specially designed for cell studies was used for the assessment of risk of bias in cell experiments (Bao et al, 2018).…”

Exosomes Derived From Epigallocatechin Gallate-Treated Cardiomyocytes Attenuated Acute Myocardial Infarction by Modulating MicroRNA-30a

“…Apoptosis and autophagy are two pivotal events of programmed cell death in the pathological mechanisms of AMI injury (Bao et al, 2018). Cardiomyocyte apoptosis and autophagy occur during sustained and severe ischemia, usually involving myocardial pump failure (Guo et al, 2019).…”

Ginkgolide B for Myocardial Ischemia/Reperfusion Injury: A Preclinical Systematic Review and Meta-Analysis

“…Some checklists have been developed to evaluate the quality of in vivo animal intervention experiments (Hooijmans et al, 2014; Zhang et al, 2017), including the SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE)'s RoB tool and the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADES) 10-item checklist. About in vitro studies, the ROB assessment can refer to 10-item scale developed by our group (Bao et al, 2018). However, there are no quality assessment tools for a systematical review of ex vivo studies.…”